Skip to content

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00607919
Enrollment
209
Registered
2008-02-06
Start date
2008-03-31
Completion date
2011-02-28
Last updated
2011-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder, Dyslexia

Brief summary

This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)

Interventions

DRUGAtomoxetine

Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks

DRUGPlacebo

oral, daily, for 16 weeks

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
10 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD) * patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient * child or adolescent patients must be 10 to 16 years old * must be able to communicate in English * must be able to swallow capsules * be reliable to keep appointments for clinic visits and all related tests

Exclusion criteria

* patients who weigh less than 25 Kg or greater than 70 Kg * patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months * patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder * females who are pregnant or breastfeeding * patients with a history of severe allergy to more than one class of medications * patients with documented history of bipolar I or bipolar II disorder, or psychosis

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 EndpointBaseline, 16 weeksMeasures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0-54. Least Square mean of change from baseline in ADHDRS is from a restricted maximum likelihood-based, mixed model repeated measures analysis which includes the effects of treatment, investigative site, baseline, visit, treatment-by-visit interaction, and baseline-by-visit interaction.

Secondary

MeasureTime frameDescription
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointBaseline, 16 weeksThe ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Change From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointBaseline, 16 weeksThe Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills.
Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointBaseline, 16 weeksThe CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better.
Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointBaseline, 16 weeksThe GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills.
Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointBaseline, 16 weeksThe TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency.
Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBaseline, 16 weeksWMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory).
Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointBaseline, 16 weeksLPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS.
Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointBaseline, 16 weeksThe K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish.
Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointBaseline, 16 weeksThe MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept).
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointBaseline, 16 weeksThe ADHDRS-IV-Parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range 0-27, and inattention scores range 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointBaseline, 32 weeksThe ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Change From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointBaseline, 32 weeksThe Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills.
Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointBaseline, 32 weeksThe CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better.
Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointBaseline, 32 weeksThe GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills.
Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointBaseline, 32 weeksThe TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency.
Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointBaseline, 32 weeksWMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory).
Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointBaseline, 32 weeksLPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS.
Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointBaseline, 32 weeksThe K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish.
Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointBaseline, 32 weeksThe MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept).
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointBaseline, 32 weeksThe ADHDRS-IV-parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.

Countries

United States

Participant flow

Pre-assignment details

The study comprised a 16-week placebo-controlled, double-blind acute phase and followed by an optional 16-week open-label in which all participants were treated with Atomoxetine.

Participants by arm

ArmCount
Atomoxetine/Atomoxetine
Participants were assigned to Atomoxetine treatment in both acute and open-label phase Atomoxetine was administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks. All eligible participants who completed the double-blind acute phase had the option of participating in a 16-week open-label extension period in which participants were treated with Atomoxetine
120
Placebo/Atomoxetine
Participants were assigned to placebo in acute phase and Atomoxetine in open-label phase. Placebo was packaged in the same way as Atomoxetine, and administered orally once daily in the morning for 16 weeks. All eligible participants who completed the double-blind acute phase had the option of participating in a 16-week open-label extension period in which participants were treated with Atomoxetine
89
Total209

Withdrawals & dropouts

PeriodReasonFG000FG001
Acute PhaseAdverse Event92
Acute PhaseEntry Criteria Not Met11
Acute PhaseLack of Efficacy12
Acute PhaseLost to Follow-up93
Acute PhaseParent/Caregiver Decision64
Acute PhaseProtocol Violation51
Acute PhaseWithdrawal by Subject33
Open-Label PhaseAdverse Event15
Open-Label PhaseLost to Follow-up41
Open-Label PhaseParent/Caregiver Decision12
Open-Label PhaseProtocol Violation22
Open-Label PhaseWithdrawal by Subject22

Baseline characteristics

CharacteristicPlacebo/AtomoxetineTotalAtomoxetine/Atomoxetine
Age Continuous12.44 years
STANDARD_DEVIATION 1.9
12.32 years
STANDARD_DEVIATION 1.8
12.24 years
STANDARD_DEVIATION 1.72
Race/Ethnicity, Customized
African
11 participants24 participants13 participants
Race/Ethnicity, Customized
Caucasian
66 participants152 participants86 participants
Race/Ethnicity, Customized
East Asian
1 participants3 participants2 participants
Race/Ethnicity, Customized
Hispanic
11 participants29 participants18 participants
Race/Ethnicity, Customized
West Asian
0 participants1 participants1 participants
Region of Enrollment
United States
89 participants209 participants120 participants
Sex: Female, Male
Female
34 Participants80 Participants46 Participants
Sex: Female, Male
Male
55 Participants129 Participants74 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
108 / 12071 / 89
serious
Total, serious adverse events
1 / 1200 / 89

Outcome results

Primary

Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint

Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0-54. Least Square mean of change from baseline in ADHDRS is from a restricted maximum likelihood-based, mixed model repeated measures analysis which includes the effects of treatment, investigative site, baseline, visit, treatment-by-visit interaction, and baseline-by-visit interaction.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint-20.01 units on a scaleStandard Error 1.45
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint-12.27 units on a scaleStandard Error 1.41
p-value: <0.001Mixed Models Analysis
Secondary

Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint

The ADHDRS-IV-Parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range 0-27, and inattention scores range 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointInattention Score-10.64 units on a scaleStandard Deviation 7.59
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointHyperactivity-Impulsivity Score-8.23 units on a scaleStandard Deviation 5.9
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointTotal Score-18.87 units on a scaleStandard Deviation 11.68
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointInattention Score-7.79 units on a scaleStandard Deviation 6.52
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointHyperactivity-Impulsivity Score-5.18 units on a scaleStandard Deviation 6.01
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointTotal Score-12.98 units on a scaleStandard Deviation 10.75
ADHD Alone: AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointHyperactivity-Impulsivity Score-6.26 units on a scaleStandard Deviation 5.1
ADHD Alone: AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointTotal Score-16.59 units on a scaleStandard Deviation 11.31
ADHD Alone: AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 EndpointInattention Score-10.33 units on a scaleStandard Deviation 7.95
Secondary

Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint

The ADHDRS-IV-parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointHyperactivity-Impulsivity Score-9.8 units on a scaleStandard Deviation 6.17
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointInattention Score-13.84 units on a scaleStandard Deviation 6.56
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointTotal Score-23.64 units on a scaleStandard Deviation 10.43
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointHyperactivity-Impulsivity Score-8.29 units on a scaleStandard Deviation 4.61
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointInattention Score-14.33 units on a scaleStandard Deviation 7.16
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 EndpointTotal Score-22.62 units on a scaleStandard Deviation 9.07
Secondary

Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint

The ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointHyperactivity-Impulsivity Score-2.71 units on a scaleStandard Deviation 3.98
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointTotal Score-7.19 units on a scaleStandard Deviation 6.83
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointInattention Score-4.48 units on a scaleStandard Deviation 5.17
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointHyperactivity-Impulsivity Score-1.99 units on a scaleStandard Deviation 6.54
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointInattention Score-0.99 units on a scaleStandard Deviation 5.33
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointTotal Score-2.98 units on a scaleStandard Deviation 10.83
ADHD Alone: AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointTotal Score-3.09 units on a scaleStandard Deviation 9.21
ADHD Alone: AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointInattention Score-2.27 units on a scaleStandard Deviation 5.24
ADHD Alone: AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 EndpointHyperactivity-Impulsivity Score-0.82 units on a scaleStandard Deviation 4.92
Secondary

Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint

The ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointHyperactivity-Impulsivity Score-1.87 unitsStandard Deviation 4.8
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointInattention Score-4.28 unitsStandard Deviation 6.08
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointTotal Score-6.15 unitsStandard Deviation 8.51
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointHyperactivity-Impulsivity Score-2.89 unitsStandard Deviation 4.48
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointInattention Score-4.19 unitsStandard Deviation 4.11
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 EndpointTotal Score-7.08 unitsStandard Deviation 7.34
Secondary

Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint

The CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointNon-word Repetition0.57 units on a scaleStandard Deviation 1.79
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Naming1.06 units on a scaleStandard Deviation 11
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointPhonological Memory2.22 units on a scaleStandard Deviation 10.61
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointPhonological Awareness5.20 units on a scaleStandard Deviation 9.49
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointBlending Words0.96 units on a scaleStandard Deviation 1.9
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Letter Naming0.31 units on a scaleStandard Deviation 1.76
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointMemory for Digits0.47 units on a scaleStandard Deviation 2.16
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointElision0.88 units on a scaleStandard Deviation 2.18
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Digit Naming0.26 units on a scaleStandard Deviation 2.06
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointPhonological Awareness2.00 units on a scaleStandard Deviation 9.34
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointBlending Words0.95 units on a scaleStandard Deviation 1.97
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointElision-0.24 units on a scaleStandard Deviation 2.34
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointMemory for Digits0.13 units on a scaleStandard Deviation 1.76
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointNon-word Repetition0.51 units on a scaleStandard Deviation 2
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointPhonological Memory0.96 units on a scaleStandard Deviation 10.16
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Digit Naming0.16 units on a scaleStandard Deviation 1.75
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Letter Naming0.24 units on a scaleStandard Deviation 1.64
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Naming0.35 units on a scaleStandard Deviation 9.75
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointMemory for Digits-0.50 units on a scaleStandard Deviation 1.9
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointBlending Words1.86 units on a scaleStandard Deviation 1.86
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Digit Naming0.23 units on a scaleStandard Deviation 1.23
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointElision0.27 units on a scaleStandard Deviation 1.91
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Naming-0.59 units on a scaleStandard Deviation 10.83
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointPhonological Awareness6.82 units on a scaleStandard Deviation 11.5
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointNon-word Repetition0.82 units on a scaleStandard Deviation 2.52
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointRapid Letter Naming0.14 units on a scaleStandard Deviation 1.52
ADHD Alone: AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 EndpointPhonological Memory1.36 units on a scaleStandard Deviation 11.33
Secondary

Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint

The CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointBlending Words1.31 units on a scaleStandard Deviation 2.01
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointElision1.07 units on a scaleStandard Deviation 2
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointMemory for Digits0.87 units on a scaleStandard Deviation 2.17
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointNon-word Repetition0.93 units on a scaleStandard Deviation 2.27
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointPhonological Awareness7.33 units on a scaleStandard Deviation 9.5
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointPhonological Memory4.93 units on a scaleStandard Deviation 10.57
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointRapid Digit Naming0.43 units on a scaleStandard Deviation 1.91
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointRapid Letter Naming0.43 units on a scaleStandard Deviation 2.06
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointRapid Naming1.30 units on a scaleStandard Deviation 11.27
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointRapid Letter Naming0.90 units on a scaleStandard Deviation 2.34
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointBlending Words1.90 units on a scaleStandard Deviation 2.98
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointPhonological Memory-0.67 units on a scaleStandard Deviation 12.44
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointElision0.71 units on a scaleStandard Deviation 3.05
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointNon-word Repetition0.43 units on a scaleStandard Deviation 3.03
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointMemory for Digits-0.05 units on a scaleStandard Deviation 2.13
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointRapid Digit Naming0.62 units on a scaleStandard Deviation 2.31
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointRapid Naming1.76 units on a scaleStandard Deviation 12.35
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 EndpointPhonological Awareness5.33 units on a scaleStandard Deviation 15.99
Secondary

Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint

The GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointOral Reading Quotient-1.43 units on a scaleStandard Deviation 23.34
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointFluency Score0.78 units on a scaleStandard Deviation 2.81
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointAccuracy Score0.71 units on a scaleStandard Deviation 2.22
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointComprehension Score0.37 units on a scaleStandard Deviation 2.35
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointRate Score0.20 units on a scaleStandard Deviation 1.65
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointFluency Score0.33 units on a scaleStandard Deviation 2.82
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointAccuracy Score0.40 units on a scaleStandard Deviation 2.02
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointComprehension Score0.65 units on a scaleStandard Deviation 2.5
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointOral Reading Quotient2.87 units on a scaleStandard Deviation 20.43
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointRate Score0.05 units on a scaleStandard Deviation 1.54
ADHD Alone: AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointRate Score0.38 units on a scaleStandard Deviation 2.27
ADHD Alone: AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointOral Reading Quotient2.43 units on a scaleStandard Deviation 10.93
ADHD Alone: AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointAccuracy Score0.95 units on a scaleStandard Deviation 2.16
ADHD Alone: AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointFluency Score1.14 units on a scaleStandard Deviation 2.94
ADHD Alone: AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 EndpointComprehension Score-0.33 units on a scaleStandard Deviation 1.93
Secondary

Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint

The GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointComprehension Score0.04 units on a scaleStandard Deviation 1.73
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointOral Reading Quotient2.64 units on a scaleStandard Deviation 15.05
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointFluency Score0.76 units on a scaleStandard Deviation 1.4
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointRate Score0.58 units on a scaleStandard Deviation 1.74
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointAccuracy Score0.82 units on a scaleStandard Deviation 1.3
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointRate Score0.15 units on a scaleStandard Deviation 1.98
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointAccuracy Score0.95 units on a scaleStandard Deviation 1.82
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointComprehension Score-0.30 units on a scaleStandard Deviation 1.59
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointFluency Score1.10 units on a scaleStandard Deviation 2.63
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 EndpointOral Reading Quotient-1.30 units on a scaleStandard Deviation 21.22
Secondary

Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint

The K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Teacher Variation (n= 22, 22, 11)-8.82 units on a scaleStandard Deviation 11.77
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Parent Variation (n= 56, 57, 23)-7.82 units on a scaleStandard Deviation 10.98
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Youth Variation (n= 56, 57, 23)-4.71 units on a scaleStandard Deviation 9.27
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Teacher Variation (n= 22, 22, 11)-1.64 units on a scaleStandard Deviation 6.53
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Parent Variation (n= 56, 57, 23)-4.64 units on a scaleStandard Deviation 9.67
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Youth Variation (n= 56, 57, 23)-4.21 units on a scaleStandard Deviation 6.85
ADHD Alone: AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Parent Variation (n= 56, 57, 23)-8.24 units on a scaleStandard Deviation 9.9
ADHD Alone: AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Youth Variation (n= 56, 57, 23)-6.17 units on a scaleStandard Deviation 7.71
ADHD Alone: AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 EndpointTotal Score-Teacher Variation (n= 22, 22, 11)-3.47 units on a scaleStandard Deviation 8.83
Secondary

Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint

The K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointTotal Score-Parent Variation (n=45, 21)-10.40 units on a scaleStandard Deviation 11.94
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointTotal Score-Teacher Variation (n=23, 9)-7.00 units on a scaleStandard Deviation 12.82
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointTotal Score-Youth Variation (n=45, 21)-4.36 units on a scaleStandard Deviation 7.57
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointTotal Score-Parent Variation (n=45, 21)-10.83 units on a scaleStandard Deviation 10.84
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointTotal Score-Teacher Variation (n=23, 9)-7.89 units on a scaleStandard Deviation 5.18
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 EndpointTotal Score-Youth Variation (n=45, 21)-5.43 units on a scaleStandard Deviation 8.44
Secondary

Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint

LPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Self Control Score6.06 units on a scaleStandard Deviation 8.54
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Happy/Social Score0.57 units on a scaleStandard Deviation 4.19
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Total Score6.51 units on a scaleStandard Deviation 11.61
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Self Control Score4.29 units on a scaleStandard Deviation 10.6
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Happy/Social Score0.53 units on a scaleStandard Deviation 4.8
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Total Score4.82 units on a scaleStandard Deviation 14.2
ADHD Alone: AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Happy/Social Score1.38 units on a scaleStandard Deviation 3.73
ADHD Alone: AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Total Score9.05 units on a scaleStandard Deviation 10.63
ADHD Alone: AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 EndpointLPS Self Control Score7.49 units on a scaleStandard Deviation 8.46
Secondary

Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint

LPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointLPS Happy/Social Score (n=45, 21)1.57 units on a scaleStandard Deviation 4.37
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointLPS Self Control Score (n=45, 20)9.10 units on a scaleStandard Deviation 10.73
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointLPS Total Score (n=45, 20)10.67 units on a scaleStandard Deviation 14.27
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointLPS Happy/Social Score (n=45, 21)2.14 units on a scaleStandard Deviation 4.3
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointLPS Self Control Score (n=45, 20)10.44 units on a scaleStandard Deviation 10.42
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 EndpointLPS Total Score (n=45, 20)12.64 units on a scaleStandard Deviation 13.95
Secondary

Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint

The MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept).

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointAffect Standard Section Score3.62 units on a scaleStandard Deviation 10.32
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointSocial Standard Section Score4.36 units on a scaleStandard Deviation 11.73
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointFamily Standard Section Score0.39 units on a scaleStandard Deviation 12.52
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointAcademic Standard Section Score5.91 units on a scaleStandard Deviation 9.01
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointPhysical Standard Section Score4.09 units on a scaleStandard Deviation 10.34
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointStandard Total Score4.72 units on a scaleStandard Deviation 9.47
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointCompetence Standard Section Score6.64 units on a scaleStandard Deviation 12.99
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointPhysical Standard Section Score1.32 units on a scaleStandard Deviation 12.06
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointAcademic Standard Section Score4.23 units on a scaleStandard Deviation 12.77
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointAffect Standard Section Score2.35 units on a scaleStandard Deviation 10.81
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointCompetence Standard Section Score4.95 units on a scaleStandard Deviation 12.05
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointFamily Standard Section Score-3.12 units on a scaleStandard Deviation 11.66
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointSocial Standard Section Score2.72 units on a scaleStandard Deviation 11.14
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointStandard Total Score1.98 units on a scaleStandard Deviation 10.19
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointCompetence Standard Section Score5.20 units on a scaleStandard Deviation 9.06
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointStandard Total Score3.44 units on a scaleStandard Deviation 7.7
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointSocial Standard Section Score3.88 units on a scaleStandard Deviation 10.39
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointAffect Standard Section Score3.56 units on a scaleStandard Deviation 10.58
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointAcademic Standard Section Score5.52 units on a scaleStandard Deviation 6.78
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointFamily Standard Section Score-1.00 units on a scaleStandard Deviation 12.26
ADHD Alone: AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 EndpointPhysical Standard Section Score3.04 units on a scaleStandard Deviation 5.99
Secondary

Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint

The MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept).

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointCompetence Standard Section Score6.76 units on a scaleStandard Deviation 11.77
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointPhysical Standard Section Score6.09 units on a scaleStandard Deviation 12
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointAffect Standard Section Score4.29 units on a scaleStandard Deviation 11.14
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointSocial Standard Section Score4.84 units on a scaleStandard Deviation 11.84
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointFamily Standard Section Score0.16 units on a scaleStandard Deviation 14.4
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointStandard Total Score5.61 units on a scaleStandard Deviation 10.82
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointAcademic Standard Section Score6.02 units on a scaleStandard Deviation 9.72
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointStandard Total Score3.48 units on a scaleStandard Deviation 7.21
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointAcademic Standard Section Score5.43 units on a scaleStandard Deviation 6.98
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointAffect Standard Section Score3.14 units on a scaleStandard Deviation 10.45
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointCompetence Standard Section Score5.19 units on a scaleStandard Deviation 7.94
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointFamily Standard Section Score0.33 units on a scaleStandard Deviation 9.79
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointPhysical Standard Section Score2.43 units on a scaleStandard Deviation 7.2
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 EndpointSocial Standard Section Score2.38 units on a scaleStandard Deviation 11.75
Secondary

Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint

The TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointSight Word Efficiency1.38 units on a scaleStandard Deviation 5.78
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointPhonemic Decoding Efficiency1.92 units on a scaleStandard Deviation 6.01
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointTotal Word Reading Efficiency Standard Score-0.57 units on a scaleStandard Deviation 21.98
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointSight Word Efficiency1.19 units on a scaleStandard Deviation 4.8
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointPhonemic Decoding Efficiency1.21 units on a scaleStandard Deviation 5.19
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointTotal Word Reading Efficiency Standard Score2.81 units on a scaleStandard Deviation 11.9
ADHD Alone: AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointPhonemic Decoding Efficiency1.77 units on a scaleStandard Deviation 6.78
ADHD Alone: AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointTotal Word Reading Efficiency Standard Score-5.88 units on a scaleStandard Deviation 25.98
ADHD Alone: AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 EndpointSight Word Efficiency0.69 units on a scaleStandard Deviation 8.84
Secondary

Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint

The TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointPhonemic Decoding Efficiency2.64 units on a scaleStandard Deviation 6.54
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointSight Word Efficiency1.93 units on a scaleStandard Deviation 6.51
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointTotal Word Reading Efficiency Standard Score2.56 units on a scaleStandard Deviation 17.35
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointPhonemic Decoding Efficiency5.33 units on a scaleStandard Deviation 6.98
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointSight Word Efficiency4.62 units on a scaleStandard Deviation 8.74
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 EndpointTotal Word Reading Efficiency Standard Score1.52 units on a scaleStandard Deviation 20.64
Secondary

Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint

The Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills.

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Comprehension (Test 9, 17)-0.08 units on a scaleStandard Deviation 9.68
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointWord Attack (Test 13)2.27 units on a scaleStandard Deviation 6.75
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Vocabulary (Test 17)0.51 units on a scaleStandard Deviation 8.92
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Fluency (Test 2)-0.24 units on a scaleStandard Deviation 7.91
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointBasic Reading Skills (Tests 1, 13)1.75 units on a scaleStandard Deviation 6.04
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointSpelling of Sounds (Test 20)5.67 units on a scaleStandard Deviation 16.07
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointPassage Comprehension (Test 9)-0.92 units on a scaleStandard Deviation 11.43
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointLetter-Word Identification (Test 1)1.18 units on a scaleStandard Deviation 7.2
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointSpelling (Test 7)-0.22 units on a scaleStandard Deviation 7.32
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Fluency (Test 2)-0.11 units on a scaleStandard Deviation 9.19
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointBasic Reading Skills (Tests 1, 13)0.87 units on a scaleStandard Deviation 6.75
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointLetter-Word Identification (Test 1)-0.07 units on a scaleStandard Deviation 6.63
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointPassage Comprehension (Test 9)-1.02 units on a scaleStandard Deviation 8.94
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Comprehension (Test 9, 17)-1.09 units on a scaleStandard Deviation 8.81
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Vocabulary (Test 17)-0.16 units on a scaleStandard Deviation 9.45
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointSpelling (Test 7)-4.16 units on a scaleStandard Deviation 12.13
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointSpelling of Sounds (Test 20)3.31 units on a scaleStandard Deviation 13.49
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointWord Attack (Test 13)1.13 units on a scaleStandard Deviation 9.75
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointPassage Comprehension (Test 9)-4.50 units on a scaleStandard Deviation 9.04
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointBasic Reading Skills (Tests 1, 13)-0.41 units on a scaleStandard Deviation 7.99
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointSpelling (Test 7)-0.41 units on a scaleStandard Deviation 5.68
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointLetter-Word Identification (Test 1)-0.32 units on a scaleStandard Deviation 8.04
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointWord Attack (Test 13)-0.36 units on a scaleStandard Deviation 7.88
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Fluency (Test 2)1.36 units on a scaleStandard Deviation 8.77
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Comprehension (Test 9, 17)-5.00 units on a scaleStandard Deviation 7.45
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointSpelling of Sounds (Test 20)8.45 units on a scaleStandard Deviation 19.78
ADHD Alone: AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 16 EndpointReading Vocabulary (Test 17)-3.95 units on a scaleStandard Deviation 8.6
Secondary

Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint

The Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills.

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointLetter-Word Identification (Test 1)1.69 units on a scaleStandard Deviation 7.19
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointReading Vocabulary (Test 17)2.60 units on a scaleStandard Deviation 8.55
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointReading Comprehension (Tests 9, 17)2.89 units on a scaleStandard Deviation 9.07
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointSpelling (Test 7)0.60 units on a scaleStandard Deviation 7.74
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointPassage Comprehension (Test 9)2.31 units on a scaleStandard Deviation 9.18
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointSpelling of Sounds (Test 20)2.98 units on a scaleStandard Deviation 10.77
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointReading Fluency (Test 2)2.69 units on a scaleStandard Deviation 9.04
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointWord Attack (Test 13)3.27 units on a scaleStandard Deviation 7.09
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointBasic Reading Skills (Tests 1, 132.73 units on a scaleStandard Deviation 6.51
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointWord Attack (Test 13)-0.90 units on a scaleStandard Deviation 6.59
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointBasic Reading Skills (Tests 1, 13-0.24 units on a scaleStandard Deviation 5.37
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointLetter-Word Identification (Test 1)0.24 units on a scaleStandard Deviation 5.73
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointPassage Comprehension (Test 9)1.24 units on a scaleStandard Deviation 5.63
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointReading Comprehension (Tests 9, 17)0.86 units on a scaleStandard Deviation 7.04
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointReading Fluency (Test 2)3.24 units on a scaleStandard Deviation 8.64
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointReading Vocabulary (Test 17)-0.14 units on a scaleStandard Deviation 10.57
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointSpelling (Test 7)0.38 units on a scaleStandard Deviation 5.96
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Woodcock-Johnson III Scores at Week 32 EndpointSpelling of Sounds (Test 20)5.90 units on a scaleStandard Deviation 14.17
Secondary

Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint

WMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory).

Time frame: Baseline, 16 weeks

Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointWord List Matching (n=54, 56, 23)-0.20 units on a scaleStandard Deviation 7.08
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointCounting Recall (n=54, 56, 23)0.50 units on a scaleStandard Deviation 4.63
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBlock Recall (n=54, 56, 23)-0.37 units on a scaleStandard Deviation 4.2
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointWord List Recall (n=54, 56, 23)1.00 units on a scaleStandard Deviation 3.29
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointVisuo-Spatial Sketchpad Score (n=47, 43, 21)4.15 units on a scaleStandard Deviation 11.96
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointNon-Word List Recall (n=53, 56, 23)0.89 units on a scaleStandard Deviation 2.74
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointPhonological Loop Component Score (n=51, 54, 21)3.57 units on a scaleStandard Deviation 10.79
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointCentral Executive Component Score (n=41, 44,12)7.34 units on a scaleStandard Deviation 10.65
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointListening Recall (n=54, 56, 23)1.52 units on a scaleStandard Deviation 3.32
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointDigit Recall (n=54, 56, 23)0.17 units on a scaleStandard Deviation 3.42
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBackward Digit Recall (n=54, 56, 23)1.30 units on a scaleStandard Deviation 3.87
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointMazes Memory (n=54, 56, 23)1.94 units on a scaleStandard Deviation 5.9
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointNon-Word List Recall (n=53, 56, 23)0.71 units on a scaleStandard Deviation 2.2
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointPhonological Loop Component Score (n=51, 54, 21)1.63 units on a scaleStandard Deviation 9
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointCentral Executive Component Score (n=41, 44,12)-0.89 units on a scaleStandard Deviation 13.65
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointVisuo-Spatial Sketchpad Score (n=47, 43, 21)-0.47 units on a scaleStandard Deviation 12.85
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointDigit Recall (n=54, 56, 23)0.55 units on a scaleStandard Deviation 3.01
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointWord List Matching (n=54, 56, 23)0.05 units on a scaleStandard Deviation 8.65
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointWord List Recall (n=54, 56, 23)0.02 units on a scaleStandard Deviation 3.15
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBlock Recall (n=54, 56, 23)-0.80 units on a scaleStandard Deviation 4.18
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointMazes Memory (n=54, 56, 23)1.18 units on a scaleStandard Deviation 5.94
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointListening Recall (n=54, 56, 23)1.00 units on a scaleStandard Deviation 3.77
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointCounting Recall (n=54, 56, 23)0.45 units on a scaleStandard Deviation 5.07
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBackward Digit Recall (n=54, 56, 23)0.16 units on a scaleStandard Deviation 3.62
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointPhonological Loop Component Score (n=51, 54, 21)2.24 units on a scaleStandard Deviation 9.78
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointMazes Memory (n=54, 56, 23)0.78 units on a scaleStandard Deviation 7.33
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointVisuo-Spatial Sketchpad Score (n=47, 43, 21)3.67 units on a scaleStandard Deviation 10.77
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointWord List Recall (n=54, 56, 23)0.35 units on a scaleStandard Deviation 2.98
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointListening Recall (n=54, 56, 23)0.04 units on a scaleStandard Deviation 5.9
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointCentral Executive Component Score (n=41, 44,12)2.17 units on a scaleStandard Deviation 11.77
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBackward Digit Recall (n=54, 56, 23)1.26 units on a scaleStandard Deviation 4.2
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointNon-Word List Recall (n=53, 56, 23)0.43 units on a scaleStandard Deviation 3.53
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointWord List Matching (n=54, 56, 23)2.04 units on a scaleStandard Deviation 9.24
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointCounting Recall (n=54, 56, 23)0.48 units on a scaleStandard Deviation 5.41
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointBlock Recall (n=54, 56, 23)0.70 units on a scaleStandard Deviation 4.24
ADHD Alone: AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 EndpointDigit Recall (n=54, 56, 23)0.22 units on a scaleStandard Deviation 4.45
Secondary

Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint

WMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory).

Time frame: Baseline, 32 weeks

Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).

ArmMeasureGroupValue (MEAN)Dispersion
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointDigit Recall (n=45, 21)-0.04 units on a scaleStandard Deviation 2.92
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointNon-Word List Recall (n=44, 21)0.55 units on a scaleStandard Deviation 2.9
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointVisuo-Spatial Sketchpad Component Score (n=40, 20)3.85 units on a scaleStandard Deviation 12.89
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointBlock Recall (n=45, 21)0.71 units on a scaleStandard Deviation 3.88
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointWord List Matching (n=45, 21)2.38 units on a scaleStandard Deviation 7.96
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointMazes Memory (n=45, 21)2.33 units on a scaleStandard Deviation 7.04
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointBackward Digit Recall (n=45, 21)1.07 units on a scaleStandard Deviation 3.24
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointListening Recall (n=45, 21)2.18 units on a scaleStandard Deviation 4.01
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointCentral Executive Component Score (n=38, 14)6.53 units on a scaleStandard Deviation 11.34
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointCounting Recall (n=45, 21)1.53 units on a scaleStandard Deviation 4.65
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointWord List Recall (n=45, 21)1.49 units on a scaleStandard Deviation 3
ADHD+ Dyslexia (D): AtomoxetineChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointPhonological Loop Component Score (n=43, 20)3.67 units on a scaleStandard Deviation 11.27
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointBackward Digit Recall (n=45, 21)2.29 units on a scaleStandard Deviation 5.2
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointPhonological Loop Component Score (n=43, 20)1.70 units on a scaleStandard Deviation 9.66
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointCentral Executive Component Score (n=38, 14)1.64 units on a scaleStandard Deviation 11.3
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointVisuo-Spatial Sketchpad Component Score (n=40, 20)2.65 units on a scaleStandard Deviation 9.96
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointDigit Recall (n=45, 21)0.52 units on a scaleStandard Deviation 4.08
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointWord List Matching (n=45, 21)1.95 units on a scaleStandard Deviation 8.22
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointWord List Recall (n=45, 21)0.33 units on a scaleStandard Deviation 2.5
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointNon-Word List Recall (n=44, 21)-0.67 units on a scaleStandard Deviation 4.39
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointBlock Recall (n=45, 21)1.05 units on a scaleStandard Deviation 4.24
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointMazes Memory (n=45, 21)3.48 units on a scaleStandard Deviation 7.77
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointListening Recall (n=45, 21)-1.05 units on a scaleStandard Deviation 6.42
ADHD+ Dyslexia (D): PlaceboChange From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 EndpointCounting Recall (n=45, 21)1.24 units on a scaleStandard Deviation 6.54

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026